Multiple Sclerosis Stem Cell Treatment

Multiple Sclerosis and Stem Cell Therapy

What is MS?

Multiple Sclerosis and Stem Cell Treatment

Multiple Sclerosis and Stem Cell Therapy

Multiple sclerosis is also known as disseminated sclerosis or encephalomyelitis disseminata.

It is an inflammatory disease where the fatty myelin sheaths around the axons of the brain and spinal cord are damaged. The disease often leads to demyelination and scarring.

The disease usually appears in young adults and is more common in women. MS affects the ability of nerve cells in the brain and spinal cord to communicate with each other.

Nerve cells communicate by sending electrical signals called action potentials down long fibers called axons, which are wrapped in an insulating substance called myelin.

In MS, the body's own immune system attacks and damages the myelin. When myelin is lost, the axons can no longer effectively conduct signals.

The name multiple sclerosis refers to scars (scleroses—better known as plaques or lesions) particularly in the white matter of the brain and spinal cord, which is mainly composed of myelin.

Although much is known about the mechanisms involved in the disease process, the cause remains unknown. There is currently no known cure for multiple sclerosis and treatments attempt to return function after an attack, prevent new attacks, and prevent disability.


Multiple Sclerosis and Stem Cell Therapy

Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation.

2011 Aug 26. [Epub ahead of print]

Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, Herrera MI, Reynolds CG, Alyea EP, Ho VT, Koreth J, Armand P, Chen YB, Ballen K, Soiffer RJ, Antin JH, Cutler CS, Ritz J.

Source Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts.

Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is associated with increased morbidity and mortality because of slow recovery of immunity and a high risk of infection. To define the differences in immune reconstitution between DUCB transplantation and HLA matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of immune reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell recipients.

Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with the MUD cohort for 1 to 6 months posttransplantation (P < .001), including naive (CD45RO-) and memory (CD45RO+) CD4 T cells, regulatory (CD4CD25) T cells, and CD8 T cells. In contrast, CD19 B cells recovered more rapidly in the DUCB cohort and numbers remained significantly greater from 3 to 24 months after transplantation (P = .001).

CD56CD16 natural killer (NK) cells also recovered more rapidly in DUCB recipients and remained significantly greater from 1 to 24 months after transplantation. B cell activating factor (BAFF) levels were higher in the DUCB cohort at 1 month (P < .001), were similar in both cohorts at 3 and 6 months, and were lower in the DUCB cohort at 12 months (P = .002). BAFF/CD19 B cell ratios were lower in the DUCB cohort at 3 (P = .045), 6 (P = .02), and 12 months (P = .002) after transplantation. DUCB recipients had more infections within the first 100 days after transplantation (P < .001), and there was less chronic graft-versus-host disease (P < .001), but there were no differences in cumulative incidence of relapse, nonrelapse death, progression-free survival, or overall survival between the 2 groups. These results suggest that increased risk of infections is specifically associated with delayed reconstitution of all major T cell subsets, but the increased risk is limited to the first 3 months after DUCB transplantation. There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings.

PMID: 21875503 [PubMed - as supplied by publisher]


Adult stem cells and multiple sclerosis.

Cell Prolif. 2011 Apr;44 Suppl 1:35-8

Authors: Scolding N

Multiple sclerosis (MS) is a common neurological disease and a major cause of disability, particularly affecting young adults.

It is characterized by patches of damage occurring throughout the brain and spinal cord, with loss of myelin sheaths - the insulating material around nerve fibres that allows normal conduction of nerve impulses - accompanied by loss of cells that make myelin (oligodendrocytes).


In addition, we now know that there is damage to nerve cells (neurones) and their fibres (axons) too, and that this occurs both within these discrete patches and in tissue between them. The cause of MS remains unknown, but an autoimmune reaction against oligodendrocytes and myelin is generally assumed to play a major role, and early acute MS lesions almost invariably show prominent inflammation.

Efforts to develop cell therapy in MS have long been directed towards directly implanting cells capable of replacing lost oligodendrocytes and regenerating myelin sheaths.

Accordingly, the advent of techniques to generate large numbers of oligodendrocytes from embryonic stem cells appeared a significant step towards new stem cell treatments for MS; while the emerging consensus that adult stem cells from, for example, the bone marrow had far less potential to turn into oligodendrocytes was thought to cast doubt on their potential value in this disease.

A number of scientific and medical concerns, not least the risk of tumour formation associated with embryonic stem cells, have however, prevented any possible clinical testing of these cells in patients.


More recently, increasing understanding of the complexity of tissue damage in MS has emphasized that successful cell therapy may need to achieve far more than simply offering a source of replacement myelin-forming cells.

The many and varied reparative properties of bone marrow-derived (mesenchymal) stem cells may well offer new and attractive possibilities for developing cell-based treatments for this difficult and disabling condition.

PMID: 21481041 [PubMed - in process]

Related Articles Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. 2015 Jan 12;212(1):23-35 Authors: Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, Wang L, Segal BM Abstract A major function of T helper (Th) 17 cells is to induce the production of factors that activate and mobilize neutrophils. Although Th17 cells have been implicated in the pathogenesis of multiple sclerosis (MS) and the animal model experimental autoimmune encephalomyelitis (EAE), little attention has been focused on the role of granulocytes in those disorders. We show that neutrophils, as well as monocytes, expand in the bone marrow and accumulate in the circulation before the clinical onset of EAE, in response to systemic up-regulation of granulocyte colony-stimulating factor (G-CSF) and the ELR(+) CXC chemokine CXCL1. Neutrophils comprised a relatively high percentage of leukocytes infiltrating the central nervous system (CNS) early in disease development. G-CSF receptor deficiency and CXCL1 blockade suppressed myeloid cell accumulation in the blood and ameliorated the clinical course of mice that were injected with myelin-reactive Th17 cells. In relapsing MS patients, plasma levels of CXCL5, another ELR(+) CXC chemokine, were elevated during acute lesion formation. Systemic expression of CXCL1, CXCL5, and neutrophil elastase correlated with measures of MS lesion burden and clinical disability. Based on these results, we advocate that neutrophil-related molecules be further investigated as novel biomarkers and therapeutic targets in MS. PMID: 25559893 [PubMed - indexed for MEDLINE]
Related Articles Mesenchymal stem cell therapy in multiple sclerosis: An updated review of the current clinical trials. Mult Scler Relat Disord. 2014 Nov;3(6):750 Authors: Mirmosayyeb O, Meamar R, Tanhaie AP, Eskandari N, Shaygannejad V Abstract INTRODUCTION: Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease of the central nervous system (CNS). The complexity of (MS) and the incompetence of a large number of promise treatments in MS urge us to plan new and more effective therapeutic approaches that aim to suppress ongoing autoimmune responses and induction of local endogenous regeneration. Stem cells (SCs) have uncovered a new view as a therapeutic tool in neurological disorders such as MS. These cells are pluripotent cells with the capacity to give rise to different cell types. There are two main stem cell types, embryonic stem cells (ESs) and adult stem cells. In adults, stem cells include hematopoietic stem cells, mesenchymal stem cells (MSCs) and neural stem cells. MSCs are self-replicating cells which can play a role in differentiating in multidirectional pathways, such as osteoblasts, chondrocytes, myocytes, marrow stromal cells, tendon-ligament fibroblasts, adipocytes and neural cells. METHODS: We studied recent (2007-2014) clinical trials and review articles of stem cell therapy for multiple sclerosis to achieve the best adult stem cell type and the most effective and safest route in order of managing them. In this article we will first provide an overview of the cell sources for, proposed mechanisms that contribute to the beneficial effects of stem cell transplantation and the ideal route and/or timing of stem cell-based therapies for MSC. RESULTS: Seven clinical trials were found (Table 1). In some studies we detect critical adverse events that has been indicated some types of SCs act as carcinogen factors. According to our research, the best stem cell to transfer MS patients was mesenchymal stem cells and injecting intravenously is the best way to administrate. By this goals we prevent from meningeal irritation that will happen in intrathecally administration. CONCLUSION: Overall, we recommend intravenous MSCs as the best kind of stem cell therapy for autoimmune disorders like MS. It is clear that more studies should be done to prove efficacy and safety of these therapeutic approaches. PMID: 25891585 [PubMed - in process]

Quick Contact Form